Showing results (151-160 of 589) with videos related to
Sort By:
Pageof 59
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|July 11, 2009
Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreasAram N Demirjian, Charles M Vollmer, David F McDermott, et al.Clinical Genitourinary Cancer|May 5, 2021
Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell CarcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.European Radiology|August 31, 2011
Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experienceIvan Pedrosa, Khashayar Rafatzand, Philip Robson, et al.Journal of Translational Medicine|April 19, 2018
The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017Paolo A Ascierto, Corrado Caracò, Jeffrey E Gershenwald, et al.Trends in Immunology|December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicitiesRobin Reschke, Ryan J Sullivan, Evan J Lipson, et al.Future Oncology (London, England)|August 1, 2023
Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinomaBrian I Rini, Michael B Atkins, Toni K Choueiri, et al.Immunotherapy|March 12, 2019
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparisonMichael B Atkins, Ahmad Tarhini, Michael Rael, et al.Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.Journal for Immunotherapy of Cancer|November 7, 2024
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanomaYu Jen Alexander Jan, Cho-Han Chiang, Soravis Osataphan, et al.European Journal of Endocrinology|June 9, 2019
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitisAlexander Faje, Kerry Reynolds, Leyre Zubiri, et al.Pageof 59